XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table

Value of Initial Fixed $100 Investment Based on:

Year

Summary Compensation Table Total for PEO (1)

Compensation Actually Paid to PEO (2)

Average Summary Compensation Table Total for Non-PEO NEOs (3)

Average Compensation Actually Paid to Non-PEO NEOs (3)

Coherus Total Shareholder Return
(TSR) (4)

Peer Group TSR (5)

Net Income (Loss)

Net Product Revenue
(Company-Selected Measure) (6)

(a)

(b)($)

(c)($)

(d)($)

(e)($)

(f)($)

(g)($)

(h)($ in 000's)

(i)($ in 000's)

2023

5,897,924

1,734,065

1,863,540

744,699

(82)

15

(237,892)

256,580

2022

6,866,396

212,826

2,122,124

470,265

(56)

11

(291,754)

210,760

2021

8,594,495

6,461,745

2,449,597

2,031,913

(11)

25

(287,100)

326,509

2020

7,278,761

8,381,980

2,035,344

2,408,072

(3)

26

132,244

475,824

(1)Represents total compensation paid to the principal executive officer, or PEO, Mr. Dennis Lanfear, as reflected in the Summary Compensation Table.

(2)The following table sets forth the adjustments made during each year presented to arrive at CAP to our PEO during each year:

2023

2022

2021

2020

($)

($)

($)

($)

Summary Compensation Table (SCT) Total Compensation

5,897,924

6,866,396

8,594,495

7,278,761

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(4,075,681)

(5,071,908)

(6,730,275)

(5,454,150)

Fair value as of year-end of equity awards granted during the year that remain unvested

1,161,479

1,795,132

3,351,633

3,953,739

Change in fair value of prior years' equity awards that remain unvested as of year-end

(1,100,382)

(2,186,702)

(576,558)

1,510,655

Fair value on vesting date for awards granted and vested in the same year

248,745

433,008

2,291,315

1,275,275

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(398,020)

(1,623,100)

(468,865)

(182,300)

Compensation Actually Paid (CAP)

1,734,065

212,826

6,461,745

8,381,980

(3)The following table sets forth the adjustments made during each year presented to arrive at CAP to our non-PEO NEOs during each year:

Graphic

2023

2022

2021

2020

($)

($)

($)

($)

Average SCT Total for Non-PEO NEOs

1,863,540

2,122,124

2,449,597

2,035,344

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(963,378)

(1,372,424)

(1,829,098)

(1,235,831)

Fair value as of year-end of equity awards granted during the year that remain unvested

260,238

537,826

1,286,137

1,037,351

Change in fair value of prior years' equity awards that remain unvested as of year-end

(229,356)

(550,147)

(108,942)

439,657

Fair value on vesting date for awards granted and vested in the same year

121,694

86,062

294,903

159,400

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(122,691)

(353,176)

(60,684)

(27,849)

Deduct fair value as of end of prior fiscal year of awards granted in any prior year that fail to meet vesting conditions during the fiscal year

(185,348)

Average CAP to Non-PEO NEOs

744,699

470,265

2,031,913

2,408,072

The non-PEO NEOs included in average compensation shown in columns (d) and (e) above are as follows:

2023

2022

2021

2020

McDavid Stilwell

McDavid Stilwell

Jean-Frederic Viret

Jean-Frederic Viret

Vladimir Vexler, Ph.D.

Vladimir Vexler, Ph.D.

McDavid Stilwell

Vincent Anicetti

Paul Reider

Vincent Anicetti

Vladimir Vexler, Ph.D.

Bryan McMichael

Vladimir Vexler, Ph.D.

(4)Total Shareholder Return, or TSR, represents the cumulative growth of a hypothetical $100 investment in the Company made as of December 31, 2020, reflected as of the end of each respective year.

(5)Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2020 in the Nasdaq Biotechnology Index, which we also use for purposes of the stock performance graph included in our Annual Report for the year ended December 31, 2023, reflected as of the end of each respective year.

(6)SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (that is not TSR or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected Net Product Revenue as this measure for 2023 as reflected in column (i) in the first table above because of our most important financial performance measures, described below, it had the most weight in determining the bonus paid to our NEOs for 2023. Net Product Revenue is the sum of the following items listed in our 2023 corporate goal performance table in the section above entitled “Compensation Discussion and Analysis”: UDENYCA® Revenue Goals; CIMERLI Revenue Goals; Toripalimab Revenue Goals and YUSIMRY Revenue Goals. Net Product Revenue is a Generally Accepted Accounting Principle measure reported in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. This performance measure may not have been the most important financial performance measure for years 2022, 2021 and 2020, and we may determine a different financial performance measure to be the most important financial performance measure in future years.
     
Company Selected Measure Name Net Product Revenue      
Named Executive Officers, Footnote
(1)Represents total compensation paid to the principal executive officer, or PEO, Mr. Dennis Lanfear, as reflected in the Summary Compensation Table.

The non-PEO NEOs included in average compensation shown in columns (d) and (e) above are as follows:

2023

2022

2021

2020

McDavid Stilwell

McDavid Stilwell

Jean-Frederic Viret

Jean-Frederic Viret

Vladimir Vexler, Ph.D.

Vladimir Vexler, Ph.D.

McDavid Stilwell

Vincent Anicetti

Paul Reider

Vincent Anicetti

Vladimir Vexler, Ph.D.

Bryan McMichael

Vladimir Vexler, Ph.D.

     
Peer Group Issuers, Footnote

(5)Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2020 in the Nasdaq Biotechnology Index, which we also use for purposes of the stock performance graph included in our Annual Report for the year ended December 31, 2023, reflected as of the end of each respective year.
     
PEO Total Compensation Amount $ 5,897,924 $ 6,866,396 $ 8,594,495 $ 7,278,761
PEO Actually Paid Compensation Amount $ 1,734,065 212,826 6,461,745 8,381,980
Adjustment To PEO Compensation, Footnote

(2)The following table sets forth the adjustments made during each year presented to arrive at CAP to our PEO during each year:

2023

2022

2021

2020

($)

($)

($)

($)

Summary Compensation Table (SCT) Total Compensation

5,897,924

6,866,396

8,594,495

7,278,761

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(4,075,681)

(5,071,908)

(6,730,275)

(5,454,150)

Fair value as of year-end of equity awards granted during the year that remain unvested

1,161,479

1,795,132

3,351,633

3,953,739

Change in fair value of prior years' equity awards that remain unvested as of year-end

(1,100,382)

(2,186,702)

(576,558)

1,510,655

Fair value on vesting date for awards granted and vested in the same year

248,745

433,008

2,291,315

1,275,275

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(398,020)

(1,623,100)

(468,865)

(182,300)

Compensation Actually Paid (CAP)

1,734,065

212,826

6,461,745

8,381,980

     
Non-PEO NEO Average Total Compensation Amount $ 1,863,540 2,122,124 2,449,597 2,035,344
Non-PEO NEO Average Compensation Actually Paid Amount $ 744,699 470,265 2,031,913 2,408,072
Adjustment to Non-PEO NEO Compensation Footnote
(3)The following table sets forth the adjustments made during each year presented to arrive at CAP to our non-PEO NEOs during each year:

Graphic

2023

2022

2021

2020

($)

($)

($)

($)

Average SCT Total for Non-PEO NEOs

1,863,540

2,122,124

2,449,597

2,035,344

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(963,378)

(1,372,424)

(1,829,098)

(1,235,831)

Fair value as of year-end of equity awards granted during the year that remain unvested

260,238

537,826

1,286,137

1,037,351

Change in fair value of prior years' equity awards that remain unvested as of year-end

(229,356)

(550,147)

(108,942)

439,657

Fair value on vesting date for awards granted and vested in the same year

121,694

86,062

294,903

159,400

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(122,691)

(353,176)

(60,684)

(27,849)

Deduct fair value as of end of prior fiscal year of awards granted in any prior year that fail to meet vesting conditions during the fiscal year

(185,348)

Average CAP to Non-PEO NEOs

744,699

470,265

2,031,913

2,408,072

     
Compensation Actually Paid vs. Total Shareholder Return

Graphic

     
Compensation Actually Paid vs. Net Income

Graphic

     
Compensation Actually Paid vs. Company Selected Measure

Graphic

     
Total Shareholder Return Vs Peer Group

Graphic

     
Tabular List, Table

TABULAR LIST OF MOST IMPORTANT FINANCIAL PERFORMANCE MEASURES

The following financial performance measures represent the most important financial measure used to link compensation actually paid to the NEOs for 2023 to Company performance: Net Product Revenue, Combined SG&A and R&D expenses and cash as of December 31, 2023.

     
Total Shareholder Return Amount $ (82) (56) (11) (3)
Peer Group Total Shareholder Return Amount 15 11 25 26
Net Income (Loss) $ (237,892,000) $ (291,754,000) $ (287,100,000) $ 132,244,000
Company Selected Measure Amount 256,580,000 210,760,000 326,509,000 475,824,000
PEO Name Mr. Dennis Lanfear      
Measure:: 1        
Pay vs Performance Disclosure        
Name Net Product Revenue      
Non-GAAP Measure Description

(6)SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (that is not TSR or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected Net Product Revenue as this measure for 2023 as reflected in column (i) in the first table above because of our most important financial performance measures, described below, it had the most weight in determining the bonus paid to our NEOs for 2023. Net Product Revenue is the sum of the following items listed in our 2023 corporate goal performance table in the section above entitled “Compensation Discussion and Analysis”: UDENYCA® Revenue Goals; CIMERLI Revenue Goals; Toripalimab Revenue Goals and YUSIMRY Revenue Goals. Net Product Revenue is a Generally Accepted Accounting Principle measure reported in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. This performance measure may not have been the most important financial performance measure for years 2022, 2021 and 2020, and we may determine a different financial performance measure to be the most important financial performance measure in future years.
     
PEO | Deduct for amounts reported under the "Stock Awards" and Option Awards" in the SCT        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (4,075,681) $ (5,071,908) $ (6,730,275) $ (5,454,150)
PEO | Fair value as of year-end of equity awards granted during the year that remain unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,161,479 1,795,132 3,351,633 3,953,739
PEO | Change in fair value of prior years' equity awards that remain unvested as of year-end        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (1,100,382) (2,186,702) (576,558) 1,510,655
PEO | Fair value on vesting date for awards granted and vested in the same year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 248,745 433,008 2,291,315 1,275,275
PEO | Change in fair value from prior year-end to vesting date of prior years' awards that vested during year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (398,020) (1,623,100) (468,865) (182,300)
Non-PEO NEO | Deduct for amounts reported under the "Stock Awards" and Option Awards" in the SCT        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (963,378) (1,372,424) (1,829,098) (1,235,831)
Non-PEO NEO | Fair value as of year-end of equity awards granted during the year that remain unvested        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 260,238 537,826 1,286,137 1,037,351
Non-PEO NEO | Change in fair value of prior years' equity awards that remain unvested as of year-end        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (229,356) (550,147) (108,942) 439,657
Non-PEO NEO | Fair value on vesting date for awards granted and vested in the same year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 121,694 86,062 294,903 159,400
Non-PEO NEO | Change in fair value from prior year-end to vesting date of prior years' awards that vested during year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (122,691) $ (353,176) $ (60,684) $ (27,849)
Non-PEO NEO | Deduct fair value as of end of prior fiscal year of awards granted in any prior year that fail to meet vesting conditions during the fiscal year        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (185,348)